BioWin launches two innovative projects to treat breast cancer and liver diseases

July 25, 2017 News BioVox

Two BioWin projects were launched a few weeks ago. The first of these, “TreatBest”, involves a consortium made up of Diagenode, IDDI, the Université Libre de Bruxelles (ULB), the Institut Jules Bordet and the University of Liège. The consortium members are pooling their expertise to support the “disruptive” science being developed at the ULB in the field of personalised breast cancer treatment. The aim of this project is to clinically validate an in vitro diagnostic test (with CE marking) that can predict the benefit of prescribing a standard anthracycline and taxane-based chemotherapy treatment for patients suffering from triple-negative breast cancer, the most aggressive form of the disease. This test will help clinicians to select the most appropriate treatment for each patient and reduce undesirable side effects, in the hope of improving their chances of recovery. The budget for this project is € 3,662,684.

The second project, “Improve”, is being led by Promethera Biosciences, a biopharmaceutical company that develops innovative cell therapies for treating liver diseases. The company is now focusing on widespread diseases with a view to expanding its product pipeline. The aim of the Improve project is to validate, at the preclinical stage, a new cell therapy product that will be ready to enter the clinical phase for the treatment of chronic fibroinflammatory liver diseases. To ensure that this project is a success, Promethera is drawing on the expertise of ImmunXperts, the paediatric hepatology laboratory and Institute for Experimental and Clinical Research (Hepato-Gastroenterology Unit) at the Université Catholique de Louvain (UCL) and the Institut Meurice. The Improve project has got a budget of € 1,269,731.

 

 


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter